首页 | 本学科首页   官方微博 | 高级检索  
检索        

参芪扶正注射液在食管癌同步放化疗中的作用
引用本文:侯激流.参芪扶正注射液在食管癌同步放化疗中的作用[J].中国煤炭工业医学杂志,2012,15(8):1244-1246.
作者姓名:侯激流
作者单位:侯激流 (467000,河南省平顶山市第二人民医院) ;
摘    要:目的观察参芪扶正注射液对食管癌同步放化疗的减毒增效作用。方法 2007年1月—2009年12月经病理证实为食管癌患者75例,参芪扶正注射液加同步放化疗者37例;单纯同步放化疗者38例。放疗均常规分割照射,DT60~65Gy/6~7周,放疗第一天及第二十九天(DT36~40Gy)时同时合并化疗,化疗为FP方案;参芪扶正注射液250ml,1~14d为1个周期,与每次同步化疗当日始。观察近期疗效、毒副反应发生情况及1、2年的生存率。结果参芪扶正联合组与放化组的近期总有效率、1年生存率、2年生存率分别为94.59%、91.89%、81.08%和89.47%、86.84%、73.68%,二组差异性无统计学意义(χ2=0.67、χ2=0.50、χ2=0.59,均P>0.05),骨髓抑制、胃肠道反应及放射性食管炎等不良反应发生率放化疗组均大于参芪扶正联合组,统计学比较差异有统计学意义(P<0.05)。结论参芪扶正注射液对食管癌同步放化疗治疗具有辐射防护、减毒增效作用,提高肿瘤患者的生存质量,值得进一步研究。

关 键 词:参芪扶正注射液  食管癌  同步放化疗

CLINICAL EFFECTATION OF SHENQIFUZHENG INJECTION COMBINED WITH CONCURRENT CHEMORADIOTHERAPY IN TREATING ESOPHAGEAL CARCINOMA
Hou Jiliu.CLINICAL EFFECTATION OF SHENQIFUZHENG INJECTION COMBINED WITH CONCURRENT CHEMORADIOTHERAPY IN TREATING ESOPHAGEAL CARCINOMA[J].Chinese Journal of Coal Industry Medicine,2012,15(8):1244-1246.
Authors:Hou Jiliu
Institution:Hou Jiliu.The Second People Hospital of Pingdingshan,Pingdingshan 467000,China
Abstract:Objective To observe the effect of Shenqifuzheng injection combined with CCRT for esophageal.Methods From January 2007 to December 2009,75 cases of esophageal were selected,include Shenqifuzheng injection combined with CCRT 37 cases and only the CCRT 38 cases.All of subjects were treated by radiotherapy with conventional segmentation,DT60-65 Gy/6-7 weeks,and treated by chemotherapy combined with radiotherapy only on the first day and the 29th day(DT36-40 Gy) for FP plan.On that day every time synchronization chemotherapy beginning,Shenqifuzheng injection was injected for 250ml,d1-14 / cycle,then the clinical effect,adverse effect and survival for one or two years were observed.Results The total effective rate for recent period,one year survival,two year survival were 94.59%,91.89%,81.08% and 89.47%,86.84%,73.68% in Shenqifuzheng injection combined with CCRT group and CCRT group respectively,there was no statistical differences in the two groups(χ2=0.67,χ2=0.50,χ2=0.59,allP>0.05).But the rates of bone marrow depression,digestive system reactions and radioactive esophagitis reactions were higher in CCRT group than that in Shenqifuzheng injection combined with CCRT group(P<0.05).Conclusion Shenqifuzheng injection combined with CCRT in the treatment of esophageal carcinoma can enhance the effect,prevent radiation,improve patients quality of life.
Keywords:Shenqifuzheng injection  Esophageal carcinoma  Concurrent chemoradiotherapy(CCRT)
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号